Online inquiry

IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5605MR)

This product GTTS-WQ5605MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5605MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5489MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ5174MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ5395MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ9675MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ13992MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ12721MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ8364MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ7015MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA F-627
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW